Zhou Mao-Ting, Zhang Peng, Mao Qi, Wei Xiao-Qin, Yang Lin, Zhang Xiao-Ming
Department of Radiology, Interventional Medical Center, Science and Technology Innovation Center, The Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China.
School of Medical Imaging, North Sichuan Medical College, Nanchong 637000, Sichuan Province, China.
World J Gastrointest Oncol. 2024 Sep 15;16(9):3752-3760. doi: 10.4251/wjgo.v16.i9.3752.
With continuous advancements in interventional radiology, considerable progress has been made in transarterial therapies for hepatocellular carcinoma (HCC) in recent years, and an increasing number of research papers on transarterial therapies for HCC have been published. In this editorial, we comment on the article by Ma published in the recent issue of the "Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable HCC". We focus specifically on the current research status and future directions of transarterial therapies. In the future, more studies are needed to determine the optimal transarterial local treatment for HCC. With the emergence of checkpoint immunotherapy modalities, it is expected that the results of trials of transarterial local therapy combined with systemic therapy will bring new hope to HCC patients.
随着介入放射学的不断进步，近年来肝细胞癌（HCC）的经动脉治疗取得了显著进展，并且发表了越来越多关于HCC经动脉治疗的研究论文。在这篇社论中，我们对马[作者姓氏]发表在最近一期《经动脉化疗栓塞联合乐伐替尼加程序性细胞死亡蛋白-1抑制治疗不可切除HCC的疗效和预测因素》上的文章进行评论。我们特别关注经动脉治疗的当前研究现状和未来方向。未来，需要更多研究来确定HCC的最佳经动脉局部治疗方法。随着检查点免疫治疗方式的出现，预计经动脉局部治疗联合全身治疗的试验结果将给HCC患者带来新希望。
